CSL Behring and BrightInsight Partner on Digital Health Solution for Patients Taking Hizentra
CSL Behring needed an underlying platform upon which they could build and operate their current and future digital health offerings. A global biotherapeutics leader specializing in innovative therapies in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas, its aim was improving treatment experiences for patients with rare and serious diseases.
After rigorous evaluation, BrightInsight was selected, as it provides a unified platform that enables CSL Behring to develop and host digital health devices, apps, algorithms and Software as a Medical Device (SaMD) at scale while maintaining compliance with global privacy, security, quality and regulatory requirements.
In this case study, we detail the first product of the CSL Behring and BrightInsight partnership: an app for adult patients taking Hizentra for Primary Immune Deficiency (PID) or for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Download the case study to learn how BrightInsight took CSL Behring from project kickoff to Hizentra app launch in six months.
Digital Health Solutions to Improve Treatment Experiences for Patients with Rare Diseases Digital Health Solutions to Improve Treatment
Biopharma and R&D